AI Summary
SciSparc’s NeuroThera Labs initiated a Phase IIb site at Hannover Medical School for SCI-110 in adults with Tourette Syndrome, with Yale and Tel Aviv centers following. Building on Phase IIa’s 21% tic reduction, the randomized, double-blind, placebo-controlled cross-over study aims to further assess efficacy and safety, potentially informing a regulatory pathway if results are favorable.
Sentiment Rationale
Phase IIb initiation and multi-site expansion represent a tangible development catalyst; positive data could improve regulatory prospects and drive upside, though outcome risk remains high given early-stage nature.
Trading Thesis
Positive Phase IIb data could lift SPRC within 6–12 months on favorable results.
Market-Moving
- Phase IIb site initiation at Hannover provides a near-term clinical catalyst for SPRC.
- Data readouts from multiple sites could drive volatility depending on results timing.
- Successful safety and efficacy signals may re-rate SPRC on TS treatment potential.
Key Facts
- SciSparc’s NeuroThera starts Phase IIb site at Hannover for SCI-110.
- Phase IIb expands to Yale and Tel Aviv centers; randomized, double-blind, cross-over.
- Phase IIa showed 21% tic reduction; primary endpoints at weeks 12 and 26.
- SCI-110 combines dronabinol with palmitoylethanolamide in a single dose.
- Tourette Syndrome is an unmet need; data could support future approvals.
Companies Mentioned
- SciSparc Ltd. (SPRC): NeuThera-led Phase IIb development of SCI-110; potential near-term catalyst for SPRC shares.
- NeuroThera Labs Inc. (NTLX): TSXV-listed subsidiary conducting the Phase IIb program; expands SciSparc’s CNS portfolio.
Industry News
Industry News: corporate development of a CNS trial milestone with potential valuation impact if results support regulatory progression.